Clinical practice in Crohn's disease in bordering regions of two countries: Different medical options, distinct surgical events

Journal of Crohn's and Colitis

Volumn 4, Issue 3, 2010, Pages 301-311

  Magro, Fernando ^a,b,c   Barreiro de Acosta, Manuel ^d,e   Lago, Paula ^a,f   Carpio, Daniel ^e,g   Cotter, José ^a,h   Echarri, Ana ^e,i   Gonçalves, Raquel ^a,j   Pereira, Santos ^e,k   Carvalho, Laura ^a,l   Lorenzo, Aurelio ^d,e   Barros, Luisa ^a,m   Castro, Javier ^e,i   Dias, Jorge Amil ^a,b   Rodrigues, Susana ^a,b   Portela, Francisco ^a,n   Dias, Camila ^a,c   da Costa Pereira, Altamiro ^a,c  

^a Portuguese Group of Studies of Inflammatory Bowel Diseases   (Portugal)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

^c University of Porto   (Portugal)

^d Instituto de Salud Carlos III   (Spain)

^e EIGA   (Spain)

^f HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^g HOSPITAL MONTECELO   (Spain)

^h Entidade Pública Empresarial   (Portugal)

ⁱ Universidad de La Coruña   (Spain)

^j HOSPITAL DE BRAGA   (Portugal)

^k HOSPITAL XERAL CÍES   (Spain)

^l Hospital de Vila Real   (Portugal)

^m Centro Hospitalar do Vale do Ave   (Portugal)

ⁿ CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

more..

Author keywords

Biologic treatment; Clinical activity; Crohn's disease; Galicia; Immunosuppression; Portugal; Predictive factors; Southern Europe; Surgery

Indexed keywords

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; CONTROLLED STUDY; CROHN DISEASE; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 77955281840     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2009.12.004     Document Type: Article

References (38)

1. Feagan B.G., Vreeland M.G., Larson L.R., Bala M.V. Annual cost of care for Crohn's disease: a payor perspective. Am J Gastroenterol 2000, 95:1955-1960.
2. Odes S., Vardi H., Friger M., Wolters F., Russel M.G., Riis L., et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10years of follow-up evaluation. Gastroenterology 2006, 131:719-728.
3. Rutgeerts P., Geboes K., Vantrappen G., Beyls J., Kerremans R., Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990, 99:956-963.
4. Candy S., Wright J., Gerber M., Adams G., Gerig M., Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995, 37:674-678.
5. Markowitz J., Hyams J., Mack D., Leleiko N., Evans J., Kugathasan S., et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1124-1129.
6. Lionetti P., Bronzini F., Salvestrini C., Bascietto C., Canani R.B., De Angelis G.L., et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003, 18:425-431.
7. Wolters F.L., Joling C., Russel M.G., Sijbrandij J., De Bruin M., Odes S., et al. Treatment inferred disease severity in Crohn's disease: evidence for a European gradient of disease course. Scand J Gastroenterol 2007, 42:333-344.
8. Magro F., Portela F., Lago P., de Deus J.R., Vieira A., Peixe P. Crohn's disease in a southern European country: Montreal classification and clinical activity. Inflamm Bowel Dis 2009, 15:1343-1350.
9. Loftus E.V., Schoenfeld P., Sandborn W.J. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment Pharmacol Ther 2002, 16:51-60.
10. Agrez M.V., Valente R.M., Pierce W., Melton L.J., van Heerden J.A., Beart R.W. Surgical history of Crohn's disease in a well-defined population. Mayo Clin Proc 1982, 57:747-752.
11. Munkholm P., Langholz E., Davidsen M., Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994, 35:360-362.
12. Munkholm P., Langholz E., Davidsen M., Binder V. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993, 105:1716-1723.
13. Binder V., Hendriksen C., Kreiner S. Prognosis in Crohn's disease-based on results from a regional patient group from the county of Copenhagen. Gut 1985, 26:146-150.
14. Jess T., Riis L., Vind I., Winther K.V., Borg S., Binder V., et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 2007, 13:481-489.
15. Ferreira A.C., Almeida S., Tavares M., Canedo P., Pereira F., Regalo G., et al. NOD2/CARD15 and TNFA, but not IL1B and IL1RN, are associated with Crohn's disease. Inflamm Bowel Dis 2005, 11:331-339.
16. Nunez C., Barreiro M., Dominguez-Munoz J.E., Lorenzo A., Zapata C., Pena A.S. CARD15 mutations in patients with Crohn's disease in a homogeneous Spanish population. Am J Gastroenterol 2004, 99:450-456.
17. Munkholm P. Crohn's disease - occurrence, course and prognosis. An epidemiologic cohort-study. Dan Med Bull 1997, 44:287-302.
18. Satsangi J., Silverberg M.S., Vermeire S., Colombel J.F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006, 55:749-753.
19. Silverstein M.D., Loftus E.V., Sandborn W.J., Tremaine W.J., Feagan B.G., Nietert P.J., et al. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999, 117:49-57.
20. Magro F., Portela F., Lago P., Deus J., Vieira A., Peixe P., Cremers I., Cotter J., Cravo M., Tavares L., Reis J., Gonçalves R., Caldeira P., Lopes H., Ministro P. A pharmaco-epidemiological approach to estimate IBD prevalence and incidence in Portugal. J Crohns Colitis 2008, 2:P099.
21. Costas Armada P., Garcia-Mayor R.V., Larranaga A., Seguin P. Prevalence and incidence of Crohn's disease in Galicia, Spain. Med Clin (Barc) 2008, 130:715.
22. Farmer R.G., Michener W.M., Mortimer E.A. Studies of family history among patients with inflammatory bowel disease. Clin Gastroenterol 1980, 9:271-277.
23. Binder V. Genetic epidemiology in inflammatory bowel disease. Dig Dis 1998, 16:351-355.
24. Yang H., Rotter J.I. Genetic aspects of idiopathic inflammatory bowel disease. Inflammatory bowel disease 1995, 301-331. Williams & Wilkins, Baltimore. 4th ed. J.B. Kirsner, R.G. Shorter (Eds.).
25. Vist G.E., Hagen K.B., Devereaux P.J., Bryant D., Kristoffersen D.T., Oxman A.D. Systematic review to determine whether participation in a trial influences outcome. BMJ 2005, 330:1175.
26. Jacobstein D.A., Mamula P., Markowitz J.E., Leonard M., Baldassano R.N. Predictors of immunomodulator use as early therapy in pediatric Crohn's disease. J Clin Gastroenterol 2006, 40:145-148.
27. Beaugerie L., Seksik P., Nion-Larmurier I., Gendre J.P., Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006, 130:650-656.
28. Loly C., Belaiche J., Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008, 43:948-954.
29. Rogers A., Kennedy A., Nelson E., Robinson A. Patients' experiences of an open access follow up arrangement in managing inflammatory bowel disease. Qual Saf Health Care 2004, 13:374-378.
30. Williams J.G., Cheung W.Y., Russell I.T., Cohen D.R., Longo M., Lervy B. Open access follow up for inflammatory bowel disease: pragmatic randomised trial and cost effectiveness study. BMJ 2000, 320:544-548.
31. Farmer R.G., Whelan G., Fazio V.W. Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology 1985, 88:1818-1825.
32. Vermeire S., van Assche G., Rutgeerts P. Review article: altering the natural history of Crohn's disease - evidence for and against current therapies. Aliment Pharmacol Ther 2007, 25:3-12.
33. Bodger K. Cost of illness of Crohn's disease. Pharmacoeconomics 2002, 20:639-652.
34. Lichtenstein G.R., Yan S., Bala M., Blank M., Sands B.E. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005, 128:862-869.
35. Feagan B.G., Panaccione R., Sandborn W.J., D'Haens G.R., Schreiber S., Rutgeerts P.J., et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008, 135:1493-1499.
36. Cosnes J., Nion-Larmurier I., Beaugerie L., Afchain P., Tiret E., Gendre J.P. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005, 54:237-241.
37. Gisbert J.P., Nino P., Cara C., Rodrigo L. Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients. Aliment Pharmacol Ther 2008, 28:228-238.
38. D'Haens G., Baert F., van Assche G., Caenepeel P., Vergauwe P., Tuynman H., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.